Economic Implications of 21-Gene Breast Cancer Risk Assay from the Perspective of an Israeli-Managed Health-Care Organization

Author： Klang Shmuel H.   Hammerman Ariel   Liebermann Nicky   Efrat Noa   Doberne Julie   Hornberger John  

Publisher： Blackwell Publishing

ISSN： 1098-3015

Source： Value in Health, Vol.13, Iss.4, 2010-06, pp. : 381-387

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Is the 21-gene recurrence score a cost-effective assay in endocrine-sensitive node-negative breast cancer?

By Lamond Nathan WD   Skedgel Chris   Younis Tallal  

Expert Review of Pharmacoeconomics and Outcomes Research, Vol. 13, Iss. 2, 2013-04 ,pp. : 243-250

Informa Healthcare

Access to resources Recommend Favorite

Epidemiology of Breast Cancer in Older Women: Implications for Future Healthcare

By Alberg A.J.   Singh S.  

Drugs & Aging, Vol. 18, Iss. 10, 2001-10 ,pp. : 761-772

Adis International

Access to resources Recommend Favorite

Consider more than just economic factors in breast cancer care

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 330, 2001-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite

Environmental Chemicals and Breast Cancer Risk - A Structural Chemistry Perspective

By  

Current Medicinal Chemistry, Vol. 15, Iss. 26, 2008-11 ,pp. : 2680-2701

Bentham Science Publishers

Access to resources Recommend Favorite

Breast cancer gene expression profiling: clinical trial and practice implications

By Loi Sherene   Desmedt Christine   Cardoso Fatima   Piccart Martine   Sotiriou Christos  

Pharmacogenomics, Vol. 6, Iss. 1, 2005-01 ,pp. : 49-58

Future Medicine

Access to resources Recommend Favorite